Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
3.922
-0.088 (-2.19%)
Streaming Delayed Price
Updated: 12:50 PM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)
↗
May 24, 2021
Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc (NASDAQ: IOVA) will benefit from its compelling tumor-...
Via
Benzinga
Cathie Wood Loads Up Yet Another $51M In Coinbase As Shares Slump Amid Bitcoin-Led Crypto Carnage
↗
May 23, 2021
Cathie Wood-led Ark Investment Management on Friday snapped up another 223,181 shares, worth about $50.7 million, in Coinbase Global Inc
Via
Benzinga
Here's Why Everyone's Talking About Iovance Biotherapeutics
↗
May 22, 2021
The CEO's unexplained departure has left investors scratching their heads.
Via
The Motley Fool
Why Iovance Biotherapeutics' Stock Is Trading Higher Today
↗
May 20, 2021
Iovance Biotherapeutics (NASDAQ:IOVA) shares are...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 20, 2021
Gainers PDS Biotechnology (NASDAQ:PDSB) shares increased by 18.99% to $6.83 during Thursday's regular session. PDS Biotechnology's stock is trading at a volume of...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
60 Biggest Movers From Yesterday
↗
May 21, 2021
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban...
Via
Benzinga
Iovance Shares Jump After Lifileucel Achieves 86% Response Rate In Melanoma Trial
↗
May 20, 2021
Yesterday the FDA asked Iovance Biotherapeutics Inc (NASDAQ: IOVA) for more data on the assays for lifileucel US application. Now the company announced ...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
↗
May 20, 2021
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03. Precipio, Inc. (NASDAQ: PRPO) gained 22.3% to $5.05. Precipio recently announced it launched a new, four-...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021
↗
May 20, 2021
Upgrades According to Argus Research, the prior rating for Vontier Corp (NYSE:VNT) was changed from Hold to Buy. In the first quarter, Vontier earned $0.63. At the moment...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
↗
May 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
↗
May 20, 2021
Keybanc lowered the price target on Micron Technology, Inc. (NASDAQ: MU) from $137 to $115. Micron shares fell 0.1% to $79.88 in pre-market trading. Goldman Sachs cut SolarEdge...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
May 20, 2021
Gainers MoSys, Inc. (NASDAQ: MOSY) shares jumped 44.1% to settle at $5.46 on Wednesday. Lianluo Smart Limited (NASDAQ: LLIT) gained 24.6% to settle at $9.22. Reata...
Via
Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
May 19, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Additional Assay Data Holdup Delays Iovance's Lifileucel Filing Again, CEO Resigns; Shares Plunge
↗
May 19, 2021
In a brief statement, Iovance Biotherapeutics Inc (NASDAQ: IOVA) company divulged that the FDA wants to see more data on the assays used to ensure each batch...
Via
Benzinga
Mid-Afternoon Market Update: Dow Falls 1%; Iovance Biotherapeutics Shares Plunge
↗
May 19, 2021
Toward the end of trading Wednesday, the Dow traded down 1.08% to 33,693.98 while the NASDAQ fell 0.66% to 13,215.41. The S&P also fell, dropping 0.94% to 4,088.99. The U.S....
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 19, 2021
Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo Smart's stock is trading at a volume of 4.6 million...
Via
Benzinga
Mid-Day Market Update: Crude Oil Down 5%; Reata Pharmaceuticals Shares Jump
↗
May 19, 2021
Midway through trading Wednesday, the Dow traded down 1.32% to 33,610.27 while the NASDAQ fell 0.89% to 13,184.68. The S&P also fell, dropping 1.20% to 4,078.44. The U.S. has...
Via
Benzinga
Topics
Stocks
Why Iovance Biotherapeutics Stock Is Crashing Today
↗
May 19, 2021
The company is delaying the FDA approval filing for cell therapy lifileucel.
Via
The Motley Fool
35 Stocks Moving In Wednesday's Mid-Day Session
↗
May 19, 2021
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares jumped 43.1% to $0.6943 after jumping over 14% on Tuesday. MoSys, Inc. (NASDAQ: MOSY) shares gained 32% to $5.00. Reata...
Via
Benzinga
Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates
↗
May 19, 2021
Following the market opening Wednesday, the Dow traded down 1.47% to 33,559.29 while the NASDAQ fell 1.29% to 13,131.99. The S&P also fell, dropping 1.42% to 4,069.40. The U.S...
Via
Benzinga
Topics
Stocks
Stocks That Hit 52-Week Lows On Wednesday
↗
May 19, 2021
On Wednesday morning, 19 companies hit new 52-week lows. Significant Points: Canadian Pacific Railway (NYSE:CP) was the largest company by market cap to set a new 52-week...
Via
Benzinga
Iovance Stock Faces A 'Not Trivial' Problem That Will Slam 2022 Sales
↗
May 19, 2021
Iovance Biotherapeutics announced another delay for its experimental cancer drug late Tuesday and IOVA stock plummeted on Wednesday.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 19, 2021
Gainers Advaxis (NASDAQ:ADXS) shares increased by 27.34% to $0.62 during Wednesday's pre-market session. The company's market cap stands at $85.2 million. Lixte...
Via
Benzinga
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
↗
May 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Iovance's Lifileucel US Application Submission Pushed To 2022
↗
May 19, 2021
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has received regulatory feedback from the FDA on its potency assays for lifileucel. Following FDA feedback, Iovance will...
Via
Benzinga
ARKK Stocks Breakdowns and Bounces
↗
May 07, 2021
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021
↗
April 16, 2021
Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Hold to Buy. In the fourth quarter, United Airlines...
Via
Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
↗
May 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
↗
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.